Loading company…
Verastem Oncology develops and commercializes medicines for cancers driven by RAS pathway mutations.
Verastem Oncology develops medicines for cancers involving mutations in the KRAS, NRAS, and HRAS genes. Its lead product, avutometinib, is a RAF/MEK clamp, and the company is also studying combination therapies. Based in Needham, US, it is led by CEO Dan Paterson. In January 2025, Oberland Capital Management provided a USD 150 million credit facility and USD 7.5 million equity investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in